Teladoc Health (TDOC) faces a closely balanced market-implied 50% probability of beating Q2 2026 earnings, scheduled for release after the July 29 close. Recent Q1 results showed an EPS miss at -$0.36 against consensus near -$0.32 alongside a modest revenue beat to $613.85 million, highlighting persistent profitability pressures amid softer BetterHelp volumes and elevated operating costs. Trader sentiment reflects this tension, with analysts maintaining a Hold consensus and price targets clustered near $7–10, while recent share-price gains of over 20% post-Q1 signal improving momentum. Key swing factors include potential upside in integrated care revenue or cost discipline that could exceed the projected EPS loss near -$0.24; any pre-release guidance revisions or utilization data could shift odds ahead of the report.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · ОновленоНОВЕ
НОВЕ
Jul 29, 2026
НОВЕ
НОВЕ
Jul 29, 2026
As of market creation, Teladoc Health is estimated to release earnings on July 29, 2026. The Street consensus estimate for Teladoc Health's GAAP EPS for the relevant quarter is $-0.25 as of market creation. This market will resolve to "Yes" if Teladoc Health reports GAAP EPS greater than $-0.25 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents.
If Teladoc Health releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Teladoc Health (TDOC) faces a closely balanced market-implied 50% probability of beating Q2 2026 earnings, scheduled for release after the July 29 close. Recent Q1 results showed an EPS miss at -$0.36 against consensus near -$0.32 alongside a modest revenue beat to $613.85 million, highlighting persistent profitability pressures amid softer BetterHelp volumes and elevated operating costs. Trader sentiment reflects this tension, with analysts maintaining a Hold consensus and price targets clustered near $7–10, while recent share-price gains of over 20% post-Q1 signal improving momentum. Key swing factors include potential upside in integrated care revenue or cost discipline that could exceed the projected EPS loss near -$0.24; any pre-release guidance revisions or utilization data could shift odds ahead of the report.
As of market creation, Teladoc Health is estimated to release earnings on July 29, 2026. The Street consensus estimate for Teladoc Health's GAAP EPS for the relevant quarter is $-0.25 as of market creation. This market will resolve to "Yes" if Teladoc Health reports GAAP EPS greater than $-0.25 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents.
If Teladoc Health releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
If Teladoc Health releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Ринок відкрито: Jul 15, 2026, 8:52 PM ET
Обсяг
$0Дата завершення
Jul 29, 2026Ринок відкрито
Jul 15, 2026, 8:52 PM ETДжерело вирішення
https://seekingalpha.com/Resolver
0x65070BE91...As of market creation, Teladoc Health is estimated to release earnings on July 29, 2026. The Street consensus estimate for Teladoc Health's GAAP EPS for the relevant quarter is $-0.25 as of market creation. This market will resolve to "Yes" if Teladoc Health reports GAAP EPS greater than $-0.25 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents.
If Teladoc Health releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Teladoc Health (TDOC) faces a closely balanced market-implied 50% probability of beating Q2 2026 earnings, scheduled for release after the July 29 close. Recent Q1 results showed an EPS miss at -$0.36 against consensus near -$0.32 alongside a modest revenue beat to $613.85 million, highlighting persistent profitability pressures amid softer BetterHelp volumes and elevated operating costs. Trader sentiment reflects this tension, with analysts maintaining a Hold consensus and price targets clustered near $7–10, while recent share-price gains of over 20% post-Q1 signal improving momentum. Key swing factors include potential upside in integrated care revenue or cost discipline that could exceed the projected EPS loss near -$0.24; any pre-release guidance revisions or utilization data could shift odds ahead of the report.
As of market creation, Teladoc Health is estimated to release earnings on July 29, 2026. The Street consensus estimate for Teladoc Health's GAAP EPS for the relevant quarter is $-0.25 as of market creation. This market will resolve to "Yes" if Teladoc Health reports GAAP EPS greater than $-0.25 for the relevant quarter in its next quarterly earnings release. Otherwise, it will resolve to "No." The resolution source will be the GAAP EPS listed in the company’s official earnings documents.
If Teladoc Health releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
If Teladoc Health releases earnings without GAAP EPS, then the market will resolve according to the GAAP EPS figure reported by SeekingAlpha. If no such figure is published within 96h of market close (4:00:00pm ET) on the day earnings are announced, the market will resolve to “No”.
If the company does not release earnings within 45 calendar days of the estimated earnings date, this market will resolve to “No.”
Note: Subsequent restatements, corrections, or revisions made to the initially announced GAAP EPS figure will not qualify for resolution, except in the case of obvious and immediate mistakes (e.g., fat finger errors, as with Lyft's (LYFT) earnings release in February 2024).
Note: The strike prices used in these markets are derived from SeekingAlpha estimates, and reflect the consensus of sell-side analyst estimates for GAAP EPS.
Note: All figures will be rounded to the nearest cent using standard rounding.
Note: For the purposes of this market, IFRS EPS will be treated as GAAP EPS.
Note: For the purposes of this market, GAAP EPS refers to diluted GAAP EPS, unless this is not published, in which case it refers to basic GAAP EPS.
Note: All figures are expressed in USD, unless otherwise indicated.
Note: For primarily internationally listed companies, this market refers specifically to the shares traded in the United States on U.S. stock exchanges such as the NYSE or Nasdaq. In cases where the company trades in the U.S. through an American Depositary Receipt (ADR) or American Depositary Share (ADS), this market will refer to the ADR/ADS.
Обсяг
$0Дата завершення
Jul 29, 2026Ринок відкрито
Jul 15, 2026, 8:52 PM ETДжерело вирішення
https://seekingalpha.com/Resolver
0x65070BE91...Teladoc Health (TDOC) faces a closely balanced market-implied 50% probability of beating Q2 2026 earnings, scheduled for release after the July 29 close. Recent Q1 results showed an EPS miss at -$0.36 against consensus near -$0.32 alongside a modest revenue beat to $613.85 million, highlighting persistent profitability pressures amid softer BetterHelp volumes and elevated operating costs. Trader sentiment reflects this tension, with analysts maintaining a Hold consensus and price targets clustered near $7–10, while recent share-price gains of over 20% post-Q1 signal improving momentum. Key swing factors include potential upside in integrated care revenue or cost discipline that could exceed the projected EPS loss near -$0.24; any pre-release guidance revisions or utilization data could shift odds ahead of the report.
Експериментальне резюме, згенероване ШІ з посиланням на дані Polymarket. Це не торгова порада і не впливає на вирішення цього ринку. · Оновлено
Обережно з зовнішніми посиланнями.
Обережно з зовнішніми посиланнями.
Часті запитання